Physician profile
Sidney Olefson
NPI 1457798506
$44,640.88
in general payments reported to CMS, 2019-2025
18 companies · $41K in 2025
The $41K reported for 2025 was more than what 97% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $202 · 2020: $124 · 2021: $11.63 · 2022: $262 · 2023: $870 · 2024: $1,922 · 2025: $41K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $43K · Food and Beverage: $1,492.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $42,549.01 |
| Food and Beverage | $1,492.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Capsovision, INC. | $42,549.01 | 2024-2025 | Capsocam Plus, Capsocam Colon |
| Abbvie INC. | $898.10 | 2019-2024 | |
| Janssen Biotech, INC. | $211.28 | 2019-2023 | Stelara |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $168.18 | 2019-2024 | Xifaxan, Trulance |
| Medtronic, INC. | $124.70 | 2022-2023 | Barrx |
| Regeneron Healthcare Solutions, INC. | $109.14 | 2023 | |
| Celgene Corporation | $101.88 | 2022-2024 | Zeposia |
| Genzyme Corporation | $88.19 | 2023-2024 | |
| Intercept Pharmaceuticals, INC. | $81.11 | 2019-2024 | |
| Pfizer INC. | $77.87 | 2023-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $77.07 | 2019-2022 | |
| Nestle Healthcare Nutrition INC. | $46.14 | 2022-2023 | |
| Ironwood Pharmaceuticals, INC | $36.15 | 2023 | Linzess |
| Cook Medical LLC | $35.38 | 2019 | |
| Gilead Sciences, INC. | $21.25 | 2023 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $15.43 | 2020 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sidney Olefson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.